Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions

Diabetes and Metabolism

Volumn 29, Issue 4 I, 2003, Pages 335-340

  Paolisso, G ^a,b   Rizzo, M R ^a   Barbieri, M ^a   Manzella, D ^a   Ragno, E ^a   Maugeri, D ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b VI Divisione di Medicina Interna   (Italy)

^c NONE

Author keywords

Cardiovascular Risk Factor; Fasting Hyperglycaemia; Post Prandial Glucose; Type 2 Diabetes

Indexed keywords

FREE RADICAL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; METFORMIN; NATEGLINIDE; NITRIC OXIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE; VOGLIBOSE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENDOTHELIUM LESION; GLUCOSE METABOLISM; GLYCATION; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; POSTPRANDIAL STATE; REVIEW; RISK ASSESSMENT; THROMBOPHILIA;

EID: 0141733189     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70044-7     Document Type: Review

References (42)

1. Avignon A, Radaucenau A, Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type2 diabetes. Diabetes Care, 1997, 20, 1822-6.
2. de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Njipels GBLM. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: The Hoorn Study. Diabetologia, 1999, 42, 926-31.
3. Del Prato S, Tiengo A. The importance of first phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes/Metabolism Research and Review, 2001, 17, 164-74.
4. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care, 1996, 19, 257-67.
5. Ceriello A. The possible role of post prandial hyperglicemia in pathogenesis of diabetic complication. Diabetologia, 2003, 46, M9-M16.
6. 1c). Diabetes Care, 2003, 26, 881-5.
7. Barrett-Connor E, Ferrara A. Isolated post-challenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. Diabetes Care, 1998, 21, 1236-9.
8. Rodriguez BL, Lau N, Burchfiel CM. Glucose tolerance and 23-year risk ofcoronary heart disease and total mortality. The Honolulu Heart Program. Diabetes Care, 1999, 22, 1262-5.
9. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationship of the glucose tolerance tests and the glycated hemoglobin assay with diabetes vascular in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract, 1992, 17, 111-23.
10. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999, 354, 617-21.
11. Hanefeld M, Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-yr follow up. Diabetologia, 1996, 39, 1577-83.
12. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellino M, de Marco R. Long term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin dependent diabetes mellitus. Circulation, 1997, 96, 1750-4.
13. Smith NL, Barzilay JL, Shaffer D, et al. Fasting and 2-hr post-challenge serum glucose measures and risk of the incident of cardiovascular events in the elderly. The cardiovascular Health Study. Arch Intern Med, 2002, 162, 209-16.
14. Balkau B, Forhan A, Eschwege E. Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia, 2002, 45, 1224-30.
15. Dornhorst A. Insulinotropic metiglinide analogues. Lancet, 2001, 358, 1709-16.
16. Bergman RN, Hope ID, Yang YJ. Assessment of insulin sensitivity in vivo: a critical review. Diabetes Metab, 1989, 15, 411-29.
17. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 2000, 133, 73-4.
18. Schmid-Antomarchi H, De Weille J, Fosset, M, Pfaff W, Lazdunski M. The receptor for antidiabetic sulphonylureas controls the activity of the ATP-modulated K-channel in insulin secreting cells. J Biol Chem, 1987, 264, 15840-4.
19. Malaisse WJ. Mechanism of action of new class of insulin secretagogues. Exp Clin Endocrinol Diabetes, 1999, 107, 140-3.
20. Owens DR. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes. Eur J Clin Invest, 1999, 29, 30-7.
21. Moses R. A review of clinical experience with prandial glucose regulator, repaglinde in the treatment of type 2 diabetes. Exp Opin Pharmacother, 2001, 67, 1455-67.
22. Masbad S, Kilhoved B, Lagert I, Mustajioki P, Dejgaard A. Comparisons between repaglinide and glipizide in type 2 diabetes mellitus: a 1 year multicentre study. Diabet Med, 2001, 18, 395-401.
23. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naïve type 2 diabetes. Diabetes Care, 2001, 24, 11-5.
24. Schmitz O, Lund S, Andersen PH, Jonler P, Porksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes double blind study with repaglinide. Diabetes Care, 2002, 25, 342-6.
25. Landgraf R, Frank M, Bauer C, Dieken ML. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obesity, 2000, 24, 38-44.
26. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes, 1999, 107, 136-9.
27. Hu S, Wang S, Fanelli B. Pancreatic beta-cell K (ATP) channel activity and membrane binding studies with nateglinide: a comparison with sulphonylureas and repaglinide. J Pharmacol Exp Ther, 2000, 293, 444-52.
28. Hu S. Interaction of nateglinide with K (ATP) channel in beta-cells underlies it unique insulinotropic action. Eur J Pharmacol, 2002, 442, 163-71.
29. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P. Differential interaction of nateglinide and repaglinide on the human beta cell sulphonylurea receptor 1. Diabetes, 2002, 51, 2789-95.
30. Foley J, Wang S, Hu S. Glucose dependent and glucose-sensitizing insulinotropic effects of nateglinide: comparison with glyburide and repaglinide. Diabetologia, 2000, 43, A491.
31. Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglyaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus. Diabet Medicine, 2000, 17, 225-9.
32. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care, 2000, 23, 1660-5.
33. Mogami H, Shibata H, Nobusawa R, Ohnota H, Satou F, Miyazaki J et al. Inhibition of ATP-sensitive K-channel by non-sulphonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Eur J Pharmacol, 1994, 269, 293-8.
34. Yamada N, Shigeta Y, Kaneko T. Hypoglycaemic effect and safety of a novel rapid-acting insulinotropic agent, KAD-1229 for NIDDM. Diabetes, 1996, 45, 74.
35. Nakashima E, Nakamura J, Koh N, Sakakibara F, Hamada Y. Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose 2,56 biphosphate content in isolated hepatocytes of normal rats. Diabetes Res Clin Pract, 1996, 34, 13-22.
36. Van Gaal LF, Leeuw IH. Rationale and options for combination therapy in the treatment oftype 2 diabetes. Diabetologia, 2003, Suppll, M44-M50.
37. Riddle M. Combining sulphonylureas and other oral agents Am J Med, 2000, 108, 15S-22S.
38. Rosenstock J, Gatlin M, mallows S, Bush C. Nateglinide improves glycemic control alone and in combination with troglitazone in patients with Type 2 patients. Diabetes, 2000, 498.
39. Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care, 2000, 23, 979-83.
40. de Luis DA, Aller R, Cuellar L, Terroba C, Ovalle H, Izaola O, Romero E. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 2001, 24, 1844-5.
41. Madsbad S. Insulin analogues: have they changed insulin treatment and improved glycaemic control? Diabetes Metab Res Rev, 2002, 18, 1, S21-8.
42. Hermansen K, Colombo M, Storgaard H, O Stergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care, 2002, 25, 883-8.